SEC Form 4 · accession 0001144204-17-044232
Moleculin Biotech, Inc. · MBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Waldemar Priebe
10% Owner
Period of report
Aug 16, 2017
Accepted (ET)
Aug 18, 2017 · 6:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001659617
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 16, 2017 | S | 100,000 | $1.703 | D | 2,781,573 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person entered into a private sale agreement for the shares of common stock set forth in the table.
- F2In addition to the shares held directly by the reporting person, The reporting person is a shareholder and control person of IntertechBio Corp. IntertechBio Corp. holds 630,000 shares of Issuer common stock. Pursuant to General Instruction 5(b)(iv) of Form 3, the amount set forth in the table represents the reporting person's proportionate interest in the Issuer common stock beneficially owned by IntertechBio Corp. The reporting person is also a shareholder and control person of Houston Pharmaceuticals, Inc. Houston Pharmaceuticals, Inc. holds 629,000 shares of Issuer common stock. Pursuant to General Instruction 5(b)(iv) of Form 3, the amount set forth in the table represents the reporting person's proportionate interest in the Issuer common stock beneficially owned by Houston Pharmaceuticals, Inc.